tiprankstipranks
The biopharmaceuticals stocks to own in 2024, according to BofA
PremiumThe FlyThe biopharmaceuticals stocks to own in 2024, according to BofA
7M ago
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
PremiumThe Fly
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
7M ago
Karuna Therapeutics price target raised to $330 from $197 at UBS
PremiumThe Fly
Karuna Therapeutics price target raised to $330 from $197 at UBS
7M ago
Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright
PremiumThe FlyKaruna deal favorable for Axsome Therapeutics, says H.C. Wainwright
7M ago
Reviva may be most undervalued in neurology, says H.C. Wainwright
PremiumThe Fly
Reviva may be most undervalued in neurology, says H.C. Wainwright
7M ago
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
7M ago
Karuna Therapeutics downgraded to Hold from Buy at Maxim
PremiumThe FlyKaruna Therapeutics downgraded to Hold from Buy at Maxim
7M ago
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
PremiumThe Fly
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
7M ago
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100